Corpus Intelligence IC Memo — NASHOBA VALLEY HOSPITAL 2026-04-26 09:05 UTC
IC Memo — NASHOBA VALLEY HOSPITAL
Investment Committee Memorandum | MA | 57 beds | Grade C | EBITDA uplift $5.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

NASHOBA VALLEY HOSPITAL

CCN 220098 | MIDDLESEX, MA | 57 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

NASHOBA VALLEY HOSPITAL is a 57-bed rural/critical access in MIDDLESEX, MA with $70.7M in net patient revenue and a -2.0% operating margin. The hospital serves a payer mix of 42.6% Medicare, 7.6% Medicaid, and 49.8% commercial.

Thesis: Turnaround. Our ML models identify $5.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -2.0% to 5.3% (+736bps).

Net Revenue HCRIS$70.7M
Current EBITDA COMPUTED$-1.4M
Operating Margin COMPUTED-2.0%
Occupancy HCRIS25.5%
Revenue / Bed COMPUTED$1.2M
Net-to-Gross HCRIS37.0%
Distress Probability ML55.9%

2. Market Context & Competitive Position

99
MA Hospitals
-12.2%
State Median Margin
33
Comparable Hospitals

MA has 99 Medicare-certified hospitals with a median operating margin of -12.2%. The target's margin of -2.0% places it above the state median. Among 33 size-comparable peers (28-114 beds), the median margin is -11.9%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (28-114), prioritizing same-state peers. 33 hospitals in the comp set.

HospitalStateBedsRevenueMargin
NASHOBA VALLEY HOSPITAL (Target)MA57$70.7M-2.0%
DANA-FARBER CANCER INSTITUTEMA30$1.88B-35.1%
EMERSON HOSPITALMA111$315.1M-10.1%
MASSACHUSETTS EYE AND EAR INFIMA41$263.9M-36.1%
NEW ENGLAND BAPTIST HOSPITALMA75$221.2M-4.6%
FALMOUTH HOSPITALMA81$172.1M-2.2%
HENRY HEYWOOD MEMORIAL HOSPITAMA114$135.6M-28.8%
BIDMC-MILTON HOSPITAL INCMA102$134.8M-11.4%
BETH ISRAEL DEACONESS HOSPITALMA58$131.9M-1.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.5M+210bp18mo
Cost to Collect4.5%2.5%$1.4M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$861K+122bp9mo
Clean Claim Rate88.0%96.0%$45K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.5M
Cost to Collect
$1.4M
Denial Rate Reduction
$1.4M
A/R Days Reduction
$861K
Clean Claim Rate
$45K
Total EBITDA Uplift$5.2M
Current EBITDA$-1.4M
+ RCM Uplift+$5.2M
Pro Forma EBITDA$3.8M
Current Margin-2.0%
Pro Forma Margin5.3%
WC Released (1x)$2.7M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-2.2M$42.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-2.2M$46.2M0.00x-100.0%
Bull Case9.0x11.0x$-2.0M$62.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-2.0M$67.8M0.00x-100.0%
Bear Case11.0x10.0x$-2.4M$17.3M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-2.4M$18.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 25.5%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 55.9% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 33 hospitals with 28-114 beds
  • Same-state prioritization (n=34)
  • Comp margins: P25=-21.0% / P50=-11.9% / P75=-0.4%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.